← boardnext 2026-08-30next 2027-06next 2028-12
GENB
Generate Biomedicinesdistress 2/10 · well-funded / low risk$13.60-2%today-22% from 52w high
Immunology / Inflammation 1
Lead: Severe Asthma · est. market ~$22B (approx, global)
Revenue
pre-revenue
Liquidity
$517M
Runway
1.6 yrs
Shares 1y
—
Price & events
+7.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-0.4%
1W
-11.9%
1M
+5.8%
3M
—
6M
—
1Y
—
2Y
—
5Y
+7.5%
All
Overview
- Market Cap
- $1.74B
- Volume
- 21.36K
- 52 Week Range
- $11.21 – $17.41
- Total Shares
- 128.19M
- Float Shares
- 60.29M
- Short %
- 7.93%
- % Held by Insiders
- 14.07%
- % Held by Institutions
- 72.90%
- RVOL
- 0.02x
Pipeline stages · 3 programs
GB-7624, Placebo
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GB-4362, enfortumab vedotin (EV), Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
GB-0895
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-30 Estimated 50% readout ~2026-09-29 final ~2026-11-30 | Phase 1 | GB-7624, Placebo | Atopic Dermatitis (AD) | 40 | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-07-01 | Phase 1 | GB-4362, enfortumab vedotin (EV), Pembrolizumab | Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | GB-0895 | Severe Asthma | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-03-17 | Phase 3 | GB-0895 | Severe Asthma | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-14Morgan StanleyOverweight
- 2026-05-08HC Wainwright & Co.Buy
- 2026-04-13HC Wainwright & Co.Buy
- 2026-03-24Goldman SachsBuy
- 2026-03-24Morgan StanleyOverweight
- 2026-03-24Piper SandlerOverweight
Competitors — Severe Asthma
Recent news
- 2026-07-22If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
- 2026-07-22Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
- 2026-07-21Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
- 2026-07-20Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
- 2026-07-13Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
- 2026-07-08Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
- 2026-06-28Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Dynamic Index - marketscreener.com
- 2026-06-28Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2500 Value Benchmark - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.